Semax Research: What the Studies Show
Semax is an analogue of the ACTH(4-10) fragment that bypasses hormonal signalling and acts directly on the central nervous system. It has an unusual evidence base for a nootropic peptide: real human stroke trials alongside detailed molecular work on BDNF and gene expression.
Mechanism of action
Semax is a synthetic heptapeptide derived from ACTH(4-10) with a Pro-Gly-Pro extension. That extension removes the hormonal (corticotropic) activity while dramatically improving stability against enzymatic breakdown.
Its best-characterised action is on the BDNF/trkB neurotrophic system — the signalling axis most closely tied to synaptic plasticity, learning and neuronal survival.
Beyond neurotrophins, genome-wide work shows Semax modulates neuroimmune crosstalk: shifting cytokine balance toward anti-inflammatory signalling and altering genes governing immune cell mobility and vascular remodelling after injury.
The studies
The stroke work below is human clinical research conducted largely in Russia; the mechanism, Alzheimer's and ADHD entries are animal and molecular studies. That distinction matters when weighing the evidence.
Ischemic stroke & neuroprotection
Mechanisms of the neuroprotective effect of Semax in acute ischemic stroke
How Semax protects threatened brain tissue during the acute phase of an ischemic stroke.
Human clinical investigation during the acute stroke period · inflammatory and neuromediator marker panel including interleukin-10, interleukin-8 and C-reactive protein
- Increased
- Interleukin-10 (anti-inflammatory)
- Suppressed
- Interleukin-8
- Suppressed
- C-reactive protein
- Semax shifted the neuromediatory balance toward anti-inflammatory agents such as interleukin-10 while suppressing pro-inflammatory pathways.
- The proposed benefit is preservation of threatened brain tissue in the penumbra — the salvageable region around the infarct core.
- This is a mechanism study in humans rather than an outcome trial: it measures markers, not recovery endpoints.
Effectiveness of Semax in the acute period of hemispheric ischemic stroke
Whether Semax accelerates functional recovery after a hemispheric ischemic stroke.
Human trial in 30 patients with acute hemispheric ischemic stroke · motor function restoration and general cerebral disorder regression endpoints
- 30
- Patients
- Accelerated
- Motor function restoration
- Regressed
- General cerebral disorders
- Treated patients showed accelerated restoration of damaged motor functions and broader regression of general cerebral disorders.
- This is the closest thing Semax has to a clinical outcome result in stroke.
- The sample is small at 30 patients, which limits how much weight the result can carry on its own.
Cognition & BDNF regulation
Semax regulates the BDNF/trkB system
Whether a single dose of Semax changes neurotrophin signalling in the hippocampus, and whether behaviour follows.
Single intranasal dose in rodents · hippocampal BDNF protein and exon III BDNF mRNA measurement · learning and conditioned avoidance behavioural testing
- 1.4× increase
- Hippocampal BDNF
- 3× increase
- Exon III BDNF mRNA
- Markedly improved
- Learning / avoidance behaviour
- A single intranasal dose produced a 1.4-fold rise in hippocampal BDNF and a 3-fold rise in exon III BDNF mRNA.
- The molecular change tracked with behaviour: learning and conditioned avoidance performance improved substantially.
- This is the mechanistic backbone of the cognitive claims made about Semax — and it is rodent data, not human.
Gene expression
Genome-wide effect of Semax on immune and vascular gene expression
Mapping which gene programmes Semax switches on and off after brain injury.
Genome-wide transcriptome analysis following experimental brain injury · differential expression of immune, cytokine and vascular gene sets
- Strongly altered
- Immune cell mobility genes
- Upregulated
- Anti-inflammatory cytokine production
- Altered
- Vascular remodelling genes
- Confirmed at genome scale that Semax's main effect is on neuroimmune crosstalk rather than a single receptor.
- After brain injury it dramatically shifts expression of genes governing immune cell mobility, anti-inflammatory cytokine output and vascular system rebuilding.
- Helps explain why the stroke findings and the cognitive findings could share one underlying mechanism.
Neurodegeneration
Semax and its derivative in Alzheimer's disease models
Whether Semax improves memory and reduces amyloid pathology in Alzheimer's models.
Transgenic Alzheimer's mouse models · Barnes maze spatial memory testing · quantification of amyloid inclusions in cortex and hippocampus
- Markedly improved
- Spatial memory (Barnes maze)
- Reduced in cortex & hippocampus
- Amyloid inclusions
- Improved spatial memory performance in the Barnes maze in transgenic Alzheimer's models.
- Reduced actual accumulation of toxic amyloid inclusions in both cortex and hippocampus — a structural change, not just a behavioural one.
- Encouraging preclinical work, but no human Alzheimer's trial of Semax exists to date.
Semax, copper-induced Aβ aggregation and artificial membrane models
Whether Semax can interfere with metal-driven amyloid-beta aggregation at the membrane.
Biophysical study in artificial membrane models · copper-induced amyloid-beta aggregation, oligomer toxicity and membrane insertion assays
- Demonstrated
- Copper chelation
- Suppressed
- Metal-induced Aβ oligomer toxicity
- Blocked
- Membrane insertion of aggregates
- Semax acts as a copper-chelating peptide, removing the metal trigger that drives a particularly toxic form of amyloid aggregation.
- It suppressed metal-induced amyloid-beta oligomer toxicity and prevented those structures from embedding into cell membranes.
- A clean molecular explanation for the amyloid reduction seen in the transgenic mouse work above.
Attention & neurodevelopment
Semax in attention-deficit hyperactivity disorder and Rett syndrome research
Whether Semax can support attention and memory through dopaminergic modulation without stimulant side effects.
Pharmacological studies of central dopamine release with and without psychostimulants · selective attention and memory endpoints
- Amplified with psychostimulants
- Central dopamine release
- Improved
- Selective attention
- Not observed
- Stimulant-type side effects
- Semax amplified central dopamine release when combined with psychostimulants, improving selective attention and memory.
- It did so without producing the jittery adverse profile typical of stimulant-only approaches.
- Positioned in the literature as a potential adjunct rather than a standalone treatment; this remains investigational.
Storage & handling
Semax is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.